Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Cagrilintide/semaglutide

REDEFINE 1

Novo Nordisk · Phase 3 · Active, not recruiting · Enrollment 3400

NCT05567796

ArmPopulationDoseWeeksEstimandWeight change
CagrisemaObesity, no T2Dcagrilintide 2.4 mg and semaglutide 2.4 mg68n/r-20.4% at week 68
CagrilintidePopulation n/rn/rn/rn/rn/r
SemaglutidePopulation n/rn/rn/rn/rn/r
Placebo s.c.Obesity, no T2Dn/r68n/r-3% at week 68